PDF下载 ( 539 KB)
Consensus for management of portal vein thrombosis in liver cirrhosis(2020,Shanghai)
-
摘要:
<正>门静脉血栓（portal vein thrombosis,PVT）是指门静脉主干和（或）门静脉左、右分支发生血栓,伴或不伴肠系膜静脉和脾静脉血栓形成。急性PVT易导致肠系膜缺血,甚至肠坏死等严重不良结局;慢性PVT可导致门静脉闭塞或门静脉海绵样变性,继发门静脉高压。肝硬化患者PVT发病隐匿,常在体格检查或筛查肝癌过程中偶然被发现,需要与恶性肿瘤导致的癌栓鉴别。由于肝硬化本身存在凝血功能障碍和出血风险的矛盾,肝硬化PVT患者的抗凝治疗难以实施。
-
Key words:
- liver cirrhosis /
- portal vein /
- venous thrombosis /
- consensus
-
[1] TSOCHATZIS EA,SENZOLO M,GERMANI G,et al. Systematic review:Portal vein thrombosis in cirrhosis[J]. Aliment Pharmacol Ther,2010,31(3):366-374. [2] CHEN HS,TRILOK G,WANG F,et al. A single hospital study on portal vein thrombosis in cirrhotic patients-clinical characteristics&risk factors[J]. Indian J Med Res,2014,139(2):260-266. [3] NERY F,CHEVRET S,CONDAT B,et al. Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis:Results of a longitudinal study[J]. Hepatology,2015,61(2):660-667. [4] NORONHA FERREIRA C,MARINHO RT,CORTEZ-PINTO H,et al. Incidence,predictive factors and clinical significance of development of portal vein thrombosis in cirrhosis:A prospective study[J]. Liver Int,2019,39(8):1459-1467. [5] ZOCCO MA,DI STASIO E,de CRISTOFARO R,et al. Thrombotic risk factors in patients with liver cirrhosis:Correlation with MELD scoring system and portal vein thrombosis development[J]. J Hepatol,2009,51(4):682-689. [6] ABDEL-RAZIK A,MOUSA N,ELHELALY R,et al. De-novo portal vein thrombosis in liver cirrhosis:Risk factors and correlation with the model for end-stage liver disease scoring system[J]. Eur J Gastroenterol Hepatol,2015,27(5):585-592. [7] ZHANG Y,XU BY,WANG XB,et al. Prevalence and clinical significance of portal vein thrombosis in patients with cirrhosis and acute decompensation[J]. Clin Gastroenterol Hepatol,2020,18(11):2564-2572. e1. [8] STINE JG,SHAH PM,CORNELLA SL,et al. Portal vein thrombosis,mortality and hepatic decompensation in patients with cirrhosis:A meta-analysis[J]. World J Hepatol,2015,7(27):2774-2780. [9] QI XS,SU CP,REN WR,et al. Association between portal vein thrombosis and risk of bleeding in liver cirrhosis:A systematic review of the literature[J]. Clin Res Hepatol Gastroenterol,2015,39(6):683-691. [10] SENZOLO M,RIVA N,DENTALI F,et al. Long-term outcome of splanchnic vein thrombosis in cirrhosis[J]. Clin Transl Gastroenterol,2018,9(8):176. [11] MCLENDON K,GOYAL A,BANSAL P,et al. Deep venous thrombosis(DVT)risk factors[M]. Treasure Island(FL):Stat Pearls Publishing,2020. [12] STINE JG,WANG J,SHAH PM,et al. Decreased portal vein velocity is predictive of the development of portal vein thrombosis:A matched case-control study[J]. Liver Int,2018,38(1):94-101. [13] TSOCHATZIS EA,BOSCH J,BURROUGHS AK. Liver cirrhosis[J]. Lancet,2014,383(9930):1749-1761. [14] XU XB,GUO XZ,de STEFANO V,et al. Nonselective betablockers and development of portal vein thrombosis in liver cirrhosis:A systematic review and meta-analysis[J]. Hepatol Int,2019,13(4):468-481. [15] LENG XS. Current status and perspectives in the management of portal hypertension[J]. Chin J Bases Clin Gen Surg,2013,20(1):1-3.(in Chinese)冷希圣．门静脉高压症治疗的现状与展望[J]．中国普外基础与临床杂志，2013,20(1):1-3. [16] QI XS,HAN GH,YE C,et al. Splenectomy causes 10-fold increased risk of portal venous system thrombosis in liver cirrhosis patients[J]. Med Sci Monit,2016,22:2528-2550. [17] INTAGLIATA NM,ARGO CK,STINE JG,et al. Concepts and controversies in haemostasis and thrombosis associated with liver disease:Proceedings of the 7th International Coagulation in Liver Disease Conference[J]. Thromb Haemost,2018,118(8):1491-1506. [18] GEMMATI D,SERINO ML,TRIVELLATO C,et al. C677T substitution in the methylenetetrahydrofolate reductase gene as a risk factor for venous thrombosis and arterial disease in selected patients[J]. Haematologica,1999,84(9):824-828. [19] SEGAL JB,BROTMAN DJ,NECOCHEA AJ,et al. Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation:A systematic review[J]. JAMA,2009,301(23):2472-2485. [20] LIPE B,ORNSTEIN DL. Deficiencies of natural anticoagulants,protein C,protein S,and antithrombin[J]. Circulation,2011,124(14):e365-e368. [21] QI X,REN W,de STEFANO V,et al. Associations of coagulation factor V Leiden and prothrombin G20210A mutations with Budd-Chiari syndrome and portal vein thrombosis:A systematic review and meta-analysis[J]. Clin Gastroenterol Hepatol,2014,12(11):1801-1812. e7. [22] MA SD,WANG J,BEZINOVER D,et al. Inherited thrombophilia and portal vein thrombosis in cirrhosis:A systematic review and meta-analysis[J]. Res Pract Thromb Haemost,2019,3(4):658-667. [23] QI X,CHEN H,HAN G. Effect of antithrombin,protein C and protein S on portal vein thrombosis in liver cirrhosis:A metaanalysis[J]. Am J Med Sci,2013,346(1):38-44. [24] HU YQ,CHEN FP,XIE QZ,et al. No association between thrombosis and factor V gene polymorphisms in Chinese Han population[J]. Thromb Haemost,2003,89(3):446-451. [25] INTAGLIATA NM,CALDWELL SH,TRIPODI A. Diagnosis,development,and treatment of portal vein thrombosis in patients with and without cirrhosis[J]. Gastroenterology,2019,156(6):1582-1599. e1. [26] SMALBERG JH,ARENDS LR,VALLA DC,et al. Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis:A meta-analysis[J]. Blood,2012,120(25):4921-4928. [27] CARNEVALE R,RAPARELLI V,NOCELLA C,et al. Gut-derived endotoxin stimulates factor VIII secretion from endothelial cells. Implications for hypercoagulability in cirrhosis[J]. J Hepatol,2017,67(5):950-956. [28] RAPARELLI V,BASILI S,CARNEVALE R,et al. Low-grade endotoxemia and platelet activation in cirrhosis[J]. Hepatology,2017,65(2):571-581. [29] HUANG XQ,FAN XW,ZHANG R,et al. Systemic inflammation and portal vein thrombosis in cirrhotic patients with gastroesophageal varices[J]. Eur J Gastroenterol Hepatol,2020,32(3):401-405. [30] MARGINI C,BERZIGOTTI A. Portal vein thrombosis:The role of imaging in the clinical setting[J]. Dig Liver Dis,2017,49(2):113-120. [31] YERDEL MA,GUNSON B,MIRZA D,et al. Portal vein thrombosis in adults undergoing liver transplantation:Risk factors,screening,management,and outcome[J]. Transplantation,2000,69(9):1873-1881. [32] de FRANCHIS R. Expanding consensus in portal hypertension:Report of the Baveno VI Consensus Workshop:Stratifying risk and individualizing care for portal hypertension[J]. J Hepatol,2015,63(3):743-752. [33] HERNNDEZ-GEA V,de GOTTARDI A,LEEBEEK FWG,et al. Current knowledge in pathophysiology and management of Budd-Chiari syndrome and non-cirrhotic non-tumoral splanchnic vein thrombosis[J]. J Hepatol,2019,71(1):175-199. [34] HAN GH,QI XS,HE CY,et al. Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with symptomatic portal hypertension in liver cirrhosis[J]. J Hepatol,2011,54(1):78-88. [35] QI XS,HAN GH,FAN DM. Management of portal vein thrombosis in liver cirrhosis[J]. Nat Rev Gastroenterol Hepatol,2014,11(7):435-446. [36] BASILI S,PASTORI D,RAPARELLI V,et al. Anticoagulant therapy in patients with liver cirrhosis and portal vein thrombosis:Insights for the clinician[J]. Therap Adv Gastroenterol,2018,11:1756284818793561. [37] DELGADO MG,SEIJO S,YEPES I,et al. Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis[J]. Clin Gastroenterol Hepatol,2012,10(7):776-783. [38] RODRIGUEZ-CASTRO KI,VITALE A,FADIN M,et al. A prediction model for successful anticoagulation in cirrhotic portal vein thrombosis[J]. Eur J Gastroenterol Hepatol,2019,31(1):34-42. [39] PLESSIER A,DARWISH-MURAD S,HERNANDEZ-GUERRA M,et al. Acute portal vein thrombosis unrelated to cirrhosis:A prospective multicenter follow-up study[J]. Hepatology,2010,51(1):210-218. [40] PLESSIER A,RAUTOU PE,VALLA DC. Management of hepatic vascular diseases[J]. J Hepatol,2012,56(Suppl 1):s25-s38. [41] QI XS,de STEFANO V,LI HY,et al. Anticoagulation for the treatment of portal vein thrombosis in liver cirrhosis:A systematic review and meta-analysis of observational studies[J].Eur J Intern Med,2015,26(1):23-29. [42] LOFFREDO L,PASTORI D,FARCOMENI A,et al. Effects of anticoagulants in patients with cirrhosis and portal vein thrombosis:A systematic review and Meta-analysis[J]. Gastroenterology,2017,153(2):480-487. e1. [43] PETTINARI I,VUKOTIC R,STEFANESCU H,et al. Clinical impact and safety of anticoagulants for portal vein thrombosis in cirrhosis[J]. Am J Gastroenterol,2019,114(2):258-266. [44] LA MURA V,BRAHAM S,TOSETTI G,et al. Harmful and beneficial effects of anticoagulants in patients with cirrhosis and portal vein thrombosis[J]. Clin Gastroenterol Hepatol,2018,16(7):1146-1152,e4. [45] ZHOU T,SUN X,ZHOU T,et al. Efficacy and safety of nadroparin calcium-warfarin sequential anticoagulation in portal vein thrombosis in cirrhotic patients:A randomized controlled trial[J]. Clin Transl Gastroenterol,2020,11(9):e00228. [46] ZHANG ZH,ZHANG JW,HE P,et al. Fondaparinux is effective for acute portal vein thrombosis in decompensated cirrhotic patients[J]. Medicine(Baltimore),2017,96(42):e8256. [47] AGNELLI G,BULLER HR,COHEN A,et al. Apixaban for extended treatment of venous thromboembolism[J]. N Engl J Med,2013,368(8):699-708. [48] BAUERSACHS R,BERKOWITZ SD,BRENNER B,et al. Oral rivaroxaban for symptomatic venous thromboembolism[J]. N Engl J Med,2010,363(26):2499-2510. [49] de GOTTARDI A,TREBICKA J,KLINGER C,et al. Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis[J]. Liver Int,2017,37(5):694-699. [50] HANAFY AS,ABD-ELSALAM S,DAWOUD MM. Randomized controlled trial of rivaroxaban versus warfarin in the management of acute non-neoplastic portal vein thrombosis[J].Vascul Pharmacol,2019,113:86-91. [51] Vascular surgery group,Branch of external Sciences,Chinese Medical Association. Guidelines for the diagnosis and treatment of deep venous thrombosis(3rd Edition)[J/CD]. Chin J Vascul Surg(Electronic Version),2017,9(4):250-257.(in Chinese)中华医学会外科学分会血管外科学组．深静脉血栓形成的诊断和治疗指南(第三版)[J/CD]．中国血管外科杂志(电子版)，2017,9(4):250-257. [52] FRANCOZ C,BELGHITI J,VILGRAIN V,et al. Splanchnic vein thrombosis in candidates for liver transplantation:Usefulness of screening and anticoagulation[J]. Gut,2005,54(5):691-697. [53] CAI MY,ZHU KS,HUANG WS,et al. Portal vein thrombosis after partial splenic embolization in liver cirrhosis:Efficacy of anticoagulation and long-term follow-up[J]. J Vasc Interv Radiol,2013,24(12):1808-1816. [54] AMITRANO L,GUARDASCIONE MA,MENCHISE A,et al.Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis[J]. J Clin Gastroenterol,2010,44(6):448-451. [55] CUI SB,SHU RH,YAN SP,et al. Efficacy and safety of anticoagulation therapy with different doses of enoxaparin for portal vein thrombosis in cirrhotic patients with hepatitis B[J]. Eur J Gastroenterol Hepatol,2015,27(8):914-919. [56] European Association for the Study of the Liver. EASL clinical practice guidelines:Vascular diseases of the liver[J]. J Hepatol,2016,64(1):179-202. [57] GERWING M,WILMS C,HEINZOW H,et al. Escalating interventional recanalization therapy in non-cirrhotic,non-malignant acute portal vein thrombosis[J]. Eur J Gastroenterol Hepatol,2019,31(12):1584-1591. [58] de SANTIS A,MOSCATELLI R,CATALANO C,et al. Systemic thrombolysis of portal vein thrombosis in cirrhotic patients:A pilot study[J]. Dig Liver Dis,2010,42(6):451-455. [59] LIU FY,WANG MQ,FAN QS,et al. Interventional treatment for symptomatic acute-subacute portal and superior mesenteric vein thrombosis[J]. World J Gastroenterol,2009,15(40):5028-5034. [60] JIANG TT,LUO XP,SUN JM,et al. Clinical outcomes of transcatheter selective superior mesenteric artery urokinase infusion therapy vs transjugular intrahepatic portosystemic shunt in patients with cirrhosis and acute portal vein thrombosis[J].World J Gastroenterol,2017,23(41):7470-7477. [61] SENZOLO M,BURRA P,PATCH D,et al. Tips for portal vein thrombosis(pvt)in cirrhosis:Not only unblocking a pipe[J].J Hepatol,2011,55(4):945-946. [62] QI XS,HE CY,GUO WG,et al. Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with variceal bleeding in liver cirrhosis:Outcomes and predictors in a prospective cohort study[J]. Liver Int,2016,36(5):667-676. [63] LV Y,QI XS,HE CY,et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis:A randomised controlled trial[J]. Gut,2018,67(12):2156-2168. [64] LUO XF,WANG Z,TSAUO J,et al. Advanced cirrhosis combined with portal vein thrombosis:A randomized trial of TIPS versus endoscopic band ligation plus propranolol for the prevention of recurrent esophageal variceal bleeding[J]. Radiology,2015,276(1):286-293. [65] WANG Z,ZHAO H,WANG XZ,et al. Clinical outcome comparison between TIPS and EBL in patients with cirrhosis and portal vein thrombosis[J]. Abdom Imaging,2015,40(6):1813-1820. [66] WANG L,HE FL,YUE ZD,et al. Techniques and long-term effects of transjugular intrahepatic portosystemic shunt on liver cirrhosis-related thrombotic total occlusion of main portal vein[J/OL]. Sci Rep,2017,7(1):10868. [67] ZHAO MF,YUE ZD,ZHAO HW,et al. Techniques of TIPS in the treatment of liver cirrhosis combined with incompletely occlusive main portal vein thrombosis[J]. Sci Rep,2016,6:33069. [68] WAN YM,LI YH,WU HM,et al. Portal vein thrombosis before and after transjugular intrahepatic portosystemic shunt placement:An observational study(STROBE compliant)[J]. Medicine(Baltimore),2017,96(45):e8498. -
本文二维码
计量
- 文章访问数: 5210
- HTML全文浏览量: 134
- PDF下载量: 585
- 被引次数: 0
下载:
